A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2029

Conditions
Advanced Melanoma
Interventions
DRUG

Pembrolizumab Injection [Keytruda]

200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.

DRUG

Metformin

500 mg, by mouth, twice a day for nine weeks.

Trial Locations (1)

15232

RECRUITING

Univ of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yana Najjar

OTHER